Abstracts tagged "autoimmune diseases"

Abstract Number: L01 • ACR Convergence 2024
Targeted Exosite Inhibition of STING Activation of TBK1 Selectively Blocks Type I Interferon and NFκB Responses for Treatment of Autoimmune Diseases
Matthew Martin¹, Erik Wilker¹, Diana Gikunju¹, Usha Narayanan¹, Unnati Pandya¹, Vijetha Prakash¹, Ashley Edwards¹, Sameer Kawatkar¹, Tenghui Chen¹, Ragunath Chandran¹, Sai Sunder¹, Sumathi Biradar¹, Joerg Distler², Alexandra Joseph¹, Stephanos Ioannidis¹ and Bhavatarini Vangamudi¹, ¹Exo Therapeutics, Cambridge, MA, ²Exo Therapeutics, Düsseldorf, Germany
Background/Purpose: The cGAS-TBK1-STING pathway senses nucleic acids for innate immunity. Aberrant activation of the pathway is linked to autoimmune diseases including Systemic and Cutaneous Lupus…
Abstract Number: L03 • ACR Convergence 2024
CD9 Expressing T Follicular Helper Cells Are a Highly Functional Subset Expanded in Systemic Lupus Erythematosus
Kyleigh Brimmer¹, Olivia Antao¹, Daniel Mayer¹, Gina Sanchez¹, Rebecca Francis¹, Htay Htay Kyi², Mary Salim², Boyan Xia², Eugenio Capitle² and Jason Weinstein¹, ¹Center for Immunity and Inflammation, Rutgers New Jersey Medical School, Newark, NJ, ²Division of Allergy, Immunology and Rheumatology, University Hospital, Newark, NJ
Background/Purpose: Systemic Lupus Erythematosus (SLE) is characterized by the generation of autoantibodies that promote tissue injury. The development of pathogenic autoantibody-secreting B cells in lupus…
Abstract Number: L10 • ACR Convergence 2024
Neuroimmune Modulation in Adults with Rheumatoid Arthritis and Inadequate Response or Intolerance to Biological or Targeted Synthetic DMARDs: Results at 12 and 24 Weeks from a Randomized, Sham-Controlled, Double-Blind Pivotal Study
John Tesser¹, Joshua June², Pendleton Wickersham³, Jane Box⁴, Guillermo Valenzuela⁵, Angela Crowley⁶, Nikila Kumar⁷, Norman Gaylis⁸, Gordan Lam⁹, David Ridley¹⁰, Gineth Paola Pinto-Patarroyo¹¹ and David Chernoff¹², ¹Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ²Great Lakes Center of Rheumatology, Lansing, MI, ³Arthritis Associates PA, San Antonio, TX, ⁴DJL Clinical Research, PLLC, Charlotte, NC, ⁵Guillermo Valenzuela MD PA/ IRIS Rheumatology, Plantation, FL, ⁶Illinois Bone and Joint Institute - Hinsdale Orthopaedics, Hinsdale, IL, ⁷Arizona Arthritis & Rheumatology Associates, Scottsdale, AZ, ⁸Arthritis & Rheumatic Disease Specialties, Aventura, FL, ⁹Arthritis & Osteoporosis Consults of the Carolinas, Charlotte, NC, ¹⁰St. Paul Rheumatology, Eagan, MN, ¹¹Annapolis Rheumatology, Fairfax, VA, ¹²SetPoint Medical, Sausalito, CA
Background/Purpose: In this study, we evaluated the safety and efficacy of an implantable, cervical vagus nerve stimulation device for treatment of RA. Methods: This randomized,…
Abstract Number: L12 • ACR Convergence 2024
A-319, a CD3 X CD19 T Cell Engager (TCE), for the Treatment of Severe/Refractory SLE: Early Evidence of Rapid Reset of Disease-Specific Autoimmunity
Chunli Mei¹, Xin Guan¹, Bin Wu², Mengjiao Li¹, Xiaojing Liu¹, Xi Chen¹, You Song¹, Weiwei Wang¹, Cheng Wang¹, Huiling Mei¹, Xiaoru Duan¹, Lijuan Jiang¹, Wenlin Qiu¹, Likai Yu¹, Yuhong Liu¹, Xing Zhao³, Xuanfan Zhong³, Shengjie Xue³, Wuzhong Shen³, Ying Tan³, Guojian Yu³, Guiyun Tu³, Hanyang Chen³, Amy Sun³, Xiaoqiang Yan³, Anbing Huang¹, Rong Du¹ and Qiubai Li¹, ¹Department of Rheumatology and Immunology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, ²Department of Rheumatology and Immunology of the First People’s Hospital of Jingzhou, Jingzhou, China, ³ITabMed Ltd. Changchun, Shanghai, China
Background/Purpose: CD19 CAR T treatment has demonstrated clinical benefits to patients with severe/refractory systemic lupus erythematosus (SLE), possibly due to resetting autoimmunity. A-319, a highly…
Abstract Number: L19 • ACR Convergence 2024
Efficacy and Safety of Emapalumab in Children and Adults with Macrophage Activation Syndrome (MAS) in Still’s Disease: Results from a Phase 3 Study and a Pooled Analysis of Two Prospective Trials
Alexei Grom¹, Uwe Ullman², Adnan Mahmood³, Josefin Blomkvist³, Brian Jamieson⁴ and Fabrizio De Benedetti⁵, ¹Cincinnati Children’s Hospital, Division of Rheumatology, Cincinnati, OH, ²Sobi, Basel, Switzerland, ³Sobi, Stockholm, Sweden, ⁴Sobi, Inc., Morrisville, NC, ⁵Bambino Gesu Children's Hospital, Rome, Italy
Background/Purpose: MAS is a life-threatening complication of Still’s disease, characterized by interferon-gamma (IFNg)-driven macrophage activation and systemic hyperinflammation. Emapalumab, an anti-IFNg antibody, binds free and…
Abstract Number: 0860 • ACR Convergence 2024
Integrated Metabolic and Immunologic Analyses Reveal Distinctive Features of Comorbid Cancer in Patients with Autoimmune Diseases
Xiangyi Shen¹, Xu Jiang², Yangzhige He² and Huaxia Yang³, ¹Tsinghua University, Beijing, China, ²National Infrastructure for Translational Medicine, Institute of Clinical Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ³Department of Rheumatology and Clinical Immunology, National Clinical Research Center for Dermatologic and Immunologic Diseases, the Ministry of Education Key Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Background/Purpose: Autoimmune diseases (AIDs) increase the risk of cancer and impose a substantial socioeconomic burden worldwide. However, the biological characteristics of cancer as a comorbidity…
Abstract Number: 0940 • ACR Convergence 2024
Trans-endothelial Migration of Synovial Fibroblasts Promotes Arthritis Severity Through a PKD1-mediated Feedback Loop
Jaeyeon Kim, Richard Ainsworth and Nunzio Bottini, Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: The application of single cell genomic approaches to the study of rheumatoid synovium has recently enabled scientists to study the complex relationship between different…
Abstract Number: 1107 • ACR Convergence 2024
Investigating Pyrexia of Unknown Origin: A Rheumatologist’s Perspective
Carine Moezinia¹, Jan Nouza², Beatrice Hornstein-Lasry², Luai Kawar², Asim Khan² and Jessica Manson², ¹University College London Hospital, London, England, United Kingdom, ²University College London Hospital, London, United Kingdom
Background/Purpose: Pyrexia of Unknown Origin (PUO) is defined as a fever above 38.3°C recorded on several occasions, that evades diagnosis for at least 3 weeks.…
Abstract Number: 1304 • ACR Convergence 2024
Assessing Knowledge and Aptitude in Antinuclear Antibody Testing Among Internal Medicine Residents
Dania Kaur¹, Fizza Zulfiqar², Akanksha Sharma³, Muhammad Bilal⁴, Rida Fatima⁴ and Abhinav Vyas⁵, ¹North Alabama Medical Center, Muscle Shoals, AL, ²Trinity Health Oakland/Wayne State University, Pontiac, MI, ³UPMC Mercy hospital, Pittsburgh, PA, Pittsburgh, PA, ⁴Bassett Medical Center, Cooperstown, NY, ⁵Vanderbilt University Medical Center, Nahville, TN
Background/Purpose: Testing for antinuclear antibodies (ANA) is essential for diagnosing autoimmune and rheumatologic diseases. The testing has become increasingly popular in primary and specialized clinics,…
Abstract Number: 1533 • ACR Convergence 2024
Imvotamab, a CD20-Targeted Bispecific IgM T Cell Engager, Effectively Depletes Low-Expressing CD20+ B Cells in Preclinical Models of Autoimmune Disease
Racquel Domingo-Gonzalez¹, Isabelle Baribaud², Shrishti Tyagi¹, Kevin Hart¹, Ryan Eberwine², Angus Sinclair¹, Albert Candia¹, Bruce Keyt¹, Merle Elloso², Maya Kotturi¹ and Mary Beth Harler¹, ¹IGM Biosciences, Inc., Mountain View, CA, ²IGM Biosciences, Inc., Doylestown, PA
Background/Purpose: B cell depletion therapy (BCDT) with conventional IgG mAbs has been employed for the treatment of autoimmune (AI) disease for ~20 years; however, many…
Abstract Number: 1659 • ACR Convergence 2024
Shared Lung and Joint T Cell Repertoire in Early Rheumatoid Arthritis Driven by Cigarette Smoking
Koen Venken¹, Matthias Jarlborg¹, Frederik Stevenaert², Thomas Malfait³, Carolien Vlieghe¹, Yann Abraham², Teddy Manuello¹, Tine Decruy¹, Stijn Van Hee¹, Hans Wils², Pieter Peeters², Philippe Carron⁴, Filip Van den Bosch³, Viggo Van Tendeloo², Bart Lambrecht¹, Ruth Wittoek⁵, Peggy Jacques⁶ and Dirk Elewaut⁷, ¹VIB Center for Inflammation Research - Ghent University, Ghent, Belgium, ²Janssen Research and Development, Beerse, Belgium, ³Ghent University Hospital, Ghent, Belgium, ⁴UZ Gent, Gent, Belgium, ⁵Dept. of Rheumatology, Ghent University Hospital, Ghent University, Ghent, Belgium, ⁶University Hospital of GHent, Gent, Belgium, ⁷Ghent University and VIB Center for Inflammation Research, Ghent, Belgium
Background/Purpose: Cigarette smoking has been associated with the production of anti-citrullinated protein antibodies (ACPA) and an increased risk of developing rheumatoid arthritis (RA) in individuals…
Abstract Number: 1787 • ACR Convergence 2024
Linking Transcriptomic Profiles of Kidney and Blood Samples Provides Insight into Identification of Lupus Nephritis
Andrea Daamen¹, Kathryn Kingsmore², Prathyusha Bachali³, Nan Shen⁴, Amrie Grammer⁵ and Peter Lipsky¹, ¹AMPEL BioSolutions, Charlottesville, VA, ²AMPEL BioSolutions, Charlottesville, ³AMPEL BioSolutions, Redmond, WA, ⁴Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jaiotong University School of Medicine, Shanghai, CN, Shanghai, China (People's Republic), ⁵AMPEL LLC, Charlottesville, VA
Background/Purpose: Current clinical methods to diagnose and evaluate the severity of lupus nephritis (LN) rely on identification of kidney dysfunction followed by invasive kidney biopsies.…
Abstract Number: 1861 • ACR Convergence 2024
CD8T Cells Depletion Promotes Human Tph/Tfh Cells Proliferation and Sjogren Syndrome Like Symptoms Without Graft versus Host Diseases in PBMC Transferred-humanized Mice
Yuzo Koda¹, Piruzyan Mariam¹, Sota Fujimori¹, Ryota Sato² and Sayuka Kato¹, ¹Mitsubishi Tanabe Pharma Corporation, Yokohama, Kanagawa, Japan, ²Mitsubishi Tanabe Pharma Corporation, Brighton, MA
Background/Purpose: Peripheral helper T (Tph) and follicular helper T (Tfh) cells are known to play a central role in the interaction between T and B…
Abstract Number: 1985 • ACR Convergence 2024
Underlying Autoimmune Disease Has Not Limited Immune Checkpoint Inhibitor Use or Increased Mortality Risk During Cancer Treatment of US Veterans
Madeline O’Sullivan¹, grant Cannon², Sauer brian³, Jorge Rojas⁴, Gary Kunkel⁵, Jessica A Walsh⁶, Punyasha Roul⁷, shardool Patel¹, Joshua Baker⁸, Bryant England⁹ and Tawnie Braaten¹, ¹University of Utah, Salt Lake City, UT, ²University of Utah and Salt Lake City VA, Salt Lake City, UT, ³Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁴Seattle VA, Mexico, Mexico, ⁵University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁶Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, ⁷UNMC, Omaha, NE, ⁸University of Pennsylvania, Philadelphia, PA, ⁹University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Immune checkpoint inhibitors (ICIs) can cause a variety of immune-related adverse events (irAEs) affecting multiple organ systems, and patients with pre-existing autoimmune disease (AID)…
Abstract Number: 2172 • ACR Convergence 2024
A Novel Cohort to Assess Longitudinal Glucocorticoid Toxicity in Individuals with Rheumatic Diseases: Objectives, Design, and Initial Baseline Characteristics
Naomi Patel¹, Miao Lin¹, Bohang Jiang¹, Isha Jha¹, Grace McMahon¹, Aubree E. McMahon¹, Yuqing Zhang², Hyon K. Choi³, Zachary Wallace⁴ and John Stone⁵, ¹Massachusetts General Hospital, Boston, MA, ²Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School; The Mongan Institute, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Massachusetts General Hospital, Lexington, MA, ⁴Massachusetts General Hospital, Newton, MA, ⁵Massachusetts General Hospital , Harvard Medical School, Concord, MA
Background/Purpose: Glucocorticoids (GC) are a backbone of treatment regimens for many rheumatic diseases despite their association with toxicities that contribute to excess morbidity and mortality.…

1
2
3
…
80
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].